Form D · Biotechnology
Gaius Therapeutics, Inc,
San Diego, CA · CIK 0002132841
Offering snapshot reported May 14, 2026 · SEC filing
- Reported sold
- $60K Offering amount: $250K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 7, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 14, 2026 | Initial | $60,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-583983
Source: Form D, filed May 14, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Javid Aceil | Executive |
| Christopher Emig | Director |
| Adam Klie | Executive |
| Michon Pinnix | Director |
| Jesse Joseph Solvason | Director, Executive |
| Ben Wang | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
9276 Scranton Road, Suite 500
San Diego, CA, 92121
San Diego, CA, 92121